We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,409

CIALIS Patent Survives Validity Challenge on Appeal
  • McCarthy Tétrault LLP
  • Canada
  • May 19 2016

Last year we wrote about a trilogy of Federal Court decisions relating to Eli Lilly’s erectile dysfunction (ED) drug CIALIS (tadalafil). While Lilly


PAB Finds Proposed Amendments Overcome Defects in Stabilized Alpha Helical Peptides Application
  • PCK Perry + Currier Inc Currier + Kao LLP
  • Canada
  • January 10 2017

It is difficult to obtain patent protection on an invention if its only described purpose is as an object of study. In this case, the Patent Appeal


Canadian patent law: 2016 year in review
  • Gowling WLG
  • Canada
  • January 4 2017

A wide variety of patent law issues were litigated and decided upon in 2016. For instance, the Supreme Court considered the law of utility, the


December 2016 International Trade Compliance
  • Baker McKenzie
  • Global, OECD, United Kingdom, USA, Australia, Canada, European Union
  • December 12 2016

On 29 November 2016, the WTO reported that most WTO members welcomed Ecuador’s efforts to lower its import surcharge rates and reduce the number of


International Trade Compliance Update - September 2016
  • Baker McKenzie
  • European Union, United Kingdom, USA, Australia, Canada
  • September 7 2016

On 19 August 2016, the Russian Federation notified the WTO that it intends to initiate negotiations pursuant to Paragraph 1143 of the Working Party


FC Rules PM(NOC) Prohibition Application Not An Abuse of Process
  • PCK Perry + Currier Inc Currier + Kao LLP
  • Canada
  • January 3 2017

The Federal Court (“FC”) has discretion as to whether or not to stay a prohibition application under the Patented Medicines (Notice of Compliance


Generic manufacturers’ applications for a Notice of Compliance did not trigger notice requirements found in Patented Medicine (Notice of Compliance) Regulations
  • Harper Grey LLP
  • Canada
  • December 20 2016

The Federal Court of Appeal allowed the appeals brought by generic drug manufacturers (Teva Canada Limited and Hospira Healthcare Corporation), the


Biosimilars in Canada: at a tipping point
  • Osler Hoskin & Harcourt LLP
  • Canada
  • May 24 2016

Biosimilars, or highly similar versions of innovative biologic medicines, have now been approved and marketed in developed countries for several


Apotex’s Infringement of AstraZeneca’s Omeprazole Formulation Patent Upheld
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • January 16 2017

The Federal Court of Appeal, in a unanimous decision released on January 12, 2017 (2017 FCA 9), has affirmed the validity of AstraZeneca's Patent No


Federal Court of Appeal clarifies test for double-patenting
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • May 12 2016

On April 20, 2016, the Federal Court of Appeal issued its decision in Mylan Pharmaceuticals ULC v Eli Lilly Canada Inc, 2016 FCA 119, a case relating